The two brightest nighttime stars available in the Shamokin sky are Sirius and Arcturus. April is the only month of the year ...

As the U.S. market navigates a turbulent landscape marked by volatile trading sessions and fluctuating economic indicators, investors are closely watching the impact of ongoing tariff developments and ...

The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

Arcturus Therapeutics (ARCT) announced that the FDA has granted fast track designation for the self-amplifying mRNA vaccine candidate, ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company ...

Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $71 and keeps a Buy rating on ...

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect ( DRRX – Research Report) today. The company’s shares opened today at $0.81.

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.